The concept of Precision Therapy in Prostate Cancer treatment will need to rely more heavily on genetic testing
Browsing: Prostate
Scott Tagawa, M.D., of Weill Cornell Medicine discusses PSMA-617 Study. At ESMO Oncology Conference – Munich, Germany On October 19,…
Scott Tagawa, M.D., Of Weill Cornell Medicine discusses Availability Of PSMA-617 Radionuclide Therapy. At ESMO Oncology Conference – Munich, Germany…
Dra. Cristina Gutierrez talks about selecting the best doctor and communicating with the physician in treating prostate cancer
SpaceOAR gel and other preventive protocols to minimize side effects for radiation therapy for prostate cancer as detailed by Dra.…
The benefits of hormonal therapy in conjunction with radiation treatment as discussed by Dra. Cristina Gutierrez
Dr. Cristina Gutierrez discusses treatment option decisions for prostate cancer
Josep Piulats, M.D., PhD, Catalan Cancer Institute discusses TRITON3 Randomized Study. At ESMO Oncology Conference – Munich, Germany On October…
Josep Piulats, M.D., PhD, Catalan Cancer Institute discusses TRITON2 Trial, Rucaparib PARP Inhibitor Data. At ESMO Oncology Conference – Munich,…
Josep Piulats, M.D., PhD, Catalan Cancer Institute discusses TRITON2 Trial Results. At ESMO Oncology Conference – Munich, Germany On October…
In this video, Andrew Armstrong, MD, from Duke University, Durham, NC, talks about the potential of the PROSPER (NCT02003924) and…
From the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Andrew Armstrong, MD, from Duke University, Durham, NC, highlights…
Bone metastases are present in the majority of patients with prostate cancer and are the main cause of mortality in…
The use of prostate-specific antigen (PSA) levels as a diagnostic test for prostate cancer has significantly reduced mortality rates, as…
From the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Francesco Montorsi, MD, from Vita-Salute San Raffaele University, Milan,…
Speaking at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Eugene Teoh, MBBS, MRCP, from the University of…
Dr. Daniel Goldstein summarizes findings of a trial presented at ASCO 2018 by Dr. Kellolumpu-Lehtinen, assessing the benefit of adjuvant…
Dr. Daniel Goldstein reviews data on the positive predictive value of PET PSMA imaging in patients with biochemically relapsed prostate…
Dr. Daniel Goldstein considers new data by Clarke & colleagues on a combination of the PARP inhibitor olaparib with abiraterone…
Dr. Daniel Goldstein reviews data by Drs. Gulley & colleagues on PROSTVAC vaccine in metastatic prostate cancer & discusses the…
With the positive results from recent trials like SPARTAN (NCT01946204) and PROSPER (NCT02003924), it is likely that drugs typically associated…
After promising efficacy data from the TROPIC trial (NCT00417079), cabazitaxel was approved for use in metastatic castration-resistant prostate cancer (mCRPC)…
Nataliya Mar, MD, UC Irvine Health, talks about Erdafitinib & Enfortumab Reached FDA Drug Designation | Will be Available in…
Dr. Daniel Goldstein reviews data in genitourinary oncology from ASCO 2018, including a study of higher dose or prolonged duration…
Dr. Daniel Goldstein summarizes key data in genitourinary oncology from ASCO 2018, including new results on pembrolizumab (Keytruda) for metastatic…
Nataliya Mar, MD, UC Irvine Health, Addressing Non-Clear Cell Histology | Did Not Come Across Any Trials at MOASC 2018
Nataliya Mar, MD, UC Irvine Health, shares her Abstracts were Metastatic Genitourinary Malignancies | Mix of Urothelial Carcinoma, Prostate Cancer,…
Promising genitourinary cancer updates were presented at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.…
Cancer vaccines are a promising immunotherapeutic area, particularly in the field of prostate cancer. Here, Neal Shore, MD, of Carolina…
Prostate cancer therapy has seen radical changes and improvements recently, with a multitude of clinical trials currently underway. Speaking from…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL, Karim Fizazi, MD, PhD, of the…
In this interview, Karim Fizazi, MD, PhD, of the University of Paris-Sud, Orsay, France gives an overview of the LATITUDE…
Nicholas J. Vogelzang, MD, shares his thoughts on imaging as an effective solution for prostate cancer diagnosis at Annual Meeting…
Nicholas J. Vogelzang, MD, talks about how MRI has improved the diagnosis of prostate cancer at Annual Meeting 2018.
Nicholas J. Vogelzang, MD, explains explains how to avoid under-diagnosing & over-diagnosing prostate cancer at Annual Meeting 2018.
Tomasz M. Beer, MD, explains how immunotherapy is being integrated into CRPC treatment algorithms at Annual Meeting 2018.
Tomasz M. Beer, MD, explains how immunotherapy is being integrated into CRPC treatment algorithms at Annual Meeting 2018.
Jeanny B. Aragon-Ching, MD, FACP, share the impact of the PROSPER and SPARTAN clinical trials at Annual Meeting 2018.
Tomasz M. Beer, MD, talks about how the the PROSPER (enzalutamide) and SPARTAN (apalutamide) studies in non-metastatic castrate-resistant prostate cancer…
Tomasz M. Beer, MD, discusses the latest trends in the multimodality treatment of prostate cancer at Annual Meeting 2018.
Celestia S. Higano, MD, shares new data being presented for metastatic CRPC at Annual Meeting 2018.
Tomasz M. Beer, MD, explains how to avoid under diagnosing and over diagnosing prostate cancer
Tomasz M. Beer, MD, explains the central themes regarding prostate cancer.
Celestia S. Higano, MD, shares her thoughts on how immunotherapy is currently being integrated into castrate resistant prostate cancer treatment…
Only a small minority of prostate cancer patients benefit from immunotherapy. Gerhardt Attard, MD, PhD, FRCP, of the Royal Marsden…
The molecular signatures of tumor cells are often used to select patients for clinical trial recruitment. In this video, Gerhardt…
Celestia S. Higano, MD, shares the outcomes from the PROSPER and SPARTAN studies in non-metastatic castrate-resistant prostate cancer are impacting…
Celestia S. Higano, MD, shares how MRIs improved the diagnosis for prostate cancers.
Celestia S. Higano, MD, talks about imaging as a cost-effective solution for diagnosis of prostate cancer.
The androgen synthesis inhibitor abiraterone increases the survival of men with metastatic prostate cancer; however, existing clinical trials consistently over-represent…
In this interview with Andrew Armstrong, MD, of Duke University, Durham, NC, speaking from the 2018 American Society of Oncology…
Osteomimicry has been studied for the last few decades, and is the process by which cancer cells can spread to…
The TroMBone trial (ISRCTN15704862), comparing radical prostatectomy with systemic therapy vs. systemic therapy alone in men with oligometastatic prostate cancer,…
Gerhardt Attard, MD, PhD, FRCP, of the The Royal Marsden NHS Foundation Trust, London, UK, speaks from the UK Oncology…
Heather H. Cheng MD, PhD, Seattle Cancer Care Alliance, discusses Gentlemen’s Study Originally for All Men in WA Now available…
Heather H. Cheng MD, PhD, Seattle Cancer Care Alliance, discusses Areas of Research in 2018-19 include Combination therapy, CARP Inhibitors,…
Heather H. Cheng MD, PhD, Seattle Cancer Care Alliance, discusses Combination Study of Olaparib & Abiraterone Especially for patients with…
Heather H. Cheng MD, PhD, Seattle Cancer Care Alliance, discusses Further Characterize Identified Mutations A lot of work to be…
Heather H. Cheng MD, PhD, Seattle Cancer Care Alliance, discusses Underserved & Underepresented Patient Population African-Americans have higher risk of…
Heather H. Cheng MD, PhD, Seattle Cancer Care Alliance, explains how Patients Can Learn More About Gentlemen’s Study from www.gentlemenstudy.org…
Heather H. Cheng MD, PhD, Seattle Cancer Care Alliance, discusses Gentlemen’s Study for Metastatic Prostate Cancer Trial offers testing in…
Heather H. Cheng MD, PhD, Seattle Cancer Care Alliance, discusses New Treatments for Prostate Cancer Identified from Tumor & Germline…